Biogen's second quarter revenue exceeded expectations.

Biogen's second quarter revenue was $2.6 billion, exceeding the estimated $2.32 billion. The adjusted earnings per share for the second quarter were $5.47. The adjusted net profit for the second quarter was $802.5 million. Tecfidera revenue for the second quarter was $193.6 million, surpassing the estimated $178 million. Avonex revenue for the second quarter was $177.7 million, exceeding the estimated $162.1 million. Plegridy revenue for the second quarter was $69 million, surpassing the estimated $59.2 million. Tysabri revenue for the second quarter was $454.6 million, exceeding the estimated $371 million. Spinraza revenue for the second quarter was $392.7 million, slightly below the estimated $399.2 million.